by The Associated Press
Teva Pharmaceuticals says it will cut 5,000 employees by the end of next year as part of a restructuring designed to slim the drugmaker's business and make it more efficient.
The Israeli company says the cuts amount to a 10 percent global workforce reduction. The drugmaker plans to trim oversized parts of its business while growing its generic and core research and development programs.
Teva says the moves are part of a global restructuring it announced in 2012. It now expects to save about $2 billion annually by the end of 2017, largely due to a reduction in the company's cost of goods.
Teva Pharmaceutical Industries Ltd. is one of the world's largest generic drugmakers. It has struggled in recent quarters with declining sales for both generic and brand-name drugs.
Explore further: Pfizer settles Protonix patent case for $2.15B
© 2013 The Associated Press. All rights reserved.
Medical Xpress on facebook
Related Stories
Pfizer settles Protonix patent case for $2.15B
Jun 12, 2013
Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.
Merck to cut 8,500 more jobs (Update)
Oct 01, 2013
Merck & Co. plans to cut another 8,500 jobs as the drugmaker continues its struggle with competition from cheaper generic medications that have squeezed the pharmaceutical industry for several quarters now.
Israeli generic drug giant Teva to buy Cephalon
May 02, 2011
Teva Pharmaceutical Industries, the world's largest generic drug maker, will buy US biopharma firm Cephalon in a $6.8 billion deal, the companies said in a joint statement Monday.
FDA approves first generic versions of Zyprexa
Oct 24, 2011
(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.
Pfizer painkiller gets longer patent protection (Update)
Mar 05, 2013
Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...
Recommended for you
Adempas approved to treat pulmonary hypertension
18 hours ago
(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.
Big data reaps big rewards in drug safety
18 hours ago
Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report ...
Gliptins: IQWiG assessed data subsequently submitted by the manufacturer
22 hours ago
The German Institute for Quality and Efficiency in Health Care (IQWiG) analysed additional data on drugs from the group of gliptins. The drug manufacturers had subsequently submitted these data to the Federal Joint Committee ...
IQWiG: Reliable assessment of drugs is only possible on the basis of clinical study reports (CSRs)
22 hours ago
In 2012 researchers from the German Institute for Quality and Efficiency in Health Care (IQWiG) presented a study in the BMJ analysing information sources used in 16 health technology assessment (HTA) reports of drugs ("benefit ...
French families file suit over alleged blood-thinner deaths
Oct 09, 2013
The families of four elderly people who died while taking an anti-clotting drug have filed a legal complaint against France's drugs safety body and Germany-based drugmaker Boehringer Ingelheim, their lawyers said Wednesday.
GSK to seek green light for malaria vaccine
Oct 08, 2013
British drug maker GlaxoSmithKline (GSK) said on Tuesday it hoped to get the green light for a prototype vaccine against malaria after trials showed it offered children a partial shield against the disease.
User comments
© Medical Xpress 2011-2013, Phys.org network
0 comments:
Post a Comment